Schaeffer's 43rd Anniversary Stock Picks in 2024

Analyst Update: Oramed Pharma, Akamai, Barnes & Noble

Analysts adjusted their ratings on Oramed Pharmaceuticals, Inc. (ORMP), Akamai Technologies, Inc. (AKAM), and Barnes & Noble, Inc. (BKS)

Apr 13, 2015 at 11:20 AM
facebook X logo linkedin


Analysts are weighing in today on drugmaker Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), cloud concern Akamai Technologies, Inc. (NASDAQ:AKAM), and book retailer Barnes & Noble, Inc. (NYSE:BKS). Here's a quick look at today's brokerage notes on ORMP, AKAM, and BKS.

  • MLV started coverage on ORMP with a "buy" opinion, and lifted its price target by $3 to $30, sending the shares up 20% to hit $7.48. The lofty target represents a 301% premium to Oramed Pharmaceuticals, Inc.'s current perch, but is in line with the shares' recent price action, up 63.8% year-to-date. Elsewhere, sentiment in the options pits has been call-heavy, as ORMP's Schaeffer's put/call open interest ratio (SOIR) of 0.47 stands in the 34th percentile of its annual range. Said another way, short-term speculators have rarely been this call-skewed on the stock over the past year. Meanwhile, short sellers could be getting antsy, as these bearish bets represent more than four weeks' worth of pent-up buying demand, at ORMP's average pace of trading.

  • CLSA cut its price target on AKAM by $1 to $82 while reaffirming its "buy" opinion, yet the shares are 0.3% higher at $71.65. On the charts, Akamai Technologies, Inc. has been a technical juggernaut, with the shares up 35.3% year-over-year. However, traders have been favoring puts over calls more than usual in the options pits, as AKAM's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.75 stands higher than 93% of all similar readings from the past year. Meanwhile, the brokerage bunch is mostly bullish on the equity, as 71% of covering analysts rate it a "strong buy," and AKAM's consensus 12-month price target of $73.95 sits in territory not charted in more than a decade.

  • The shares of BKS are 6.7% higher at $23.77, after Craig-Hallum initiated coverage on the security with a "buy" rating and a $36 price target -- a level not conquered since early 2008. Furthermore, today's bump pulls of the shares out of the red for 2015, now up 2.5% year-to-date. Calls have been prominent in the options pits, as Barnes & Noble, Inc.'s 50-day ISE/CBOE/PHLX call/put volume ratio of 4.83 reads in the 80th percentile of its annual range. However, not all analysts have boarded the bullish bandwagon: just one of four brokerage firms offers up a "strong buy" endorsement.
 

A.I.’s Dirty Little Secret: The Real Power Behind The AI. Boom ✨

Anyone who’s seen the The Matrix movies knows that A.I. needs power.  Lots and lots of power.

If you’ve seen the movie, you also know the grizzly results of the ensuing battle for that power.

Now, Wall Street’s battle for A.I. power won’t go to such extremes. Hopefully?

A.I. needs more power and that means more opportunities for stock traders in the know.

Download your free copy of “The A.I. Revolution: 4 Stocks to Buy Now”!